Materiality pending
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
- Veracyte's shares rose by 6% post-earnings, with an earnings surprise average of 59.65%. - Expected 11.9% earnings growth in 2024, with revenues expected between $402-410 million. - Continued market share growth with Afirma solution and new acquisition of C2i Genomics. - Strong cash position, no current debt, and rising current ratio to 5.00. - Zacks consensus estimate for 2025 moved up from 1 cent to 7 cents. Price Impact Rating: bullish Impact Horizon Rating: long-term Type: Research Analysis
- Veracyte's shares rose by 6% post-earnings, with an earnings surprise average of 59.65%.
- Expected 11.9% earnings growth in 2024, with revenues expected between $402-410 million.
- Continued market share growth with Afirma solution and new acquisition of C2i Genomics.
- Strong cash position, no current debt, and rising current ratio to 5.00.
- Zacks consensus estimate for 2025 moved up from 1 cent to 7 cents.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.